Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome

被引:73
作者
Lee, Ho Yung
Choi, Hoon Young
Park, Hyeong Cheon
Seo, Bo Jeung
Do, Jun Young
Yun, Sung Ro
Song, Hyun Yong
Kim, Yeong Hoon
Kim, Yong-Lim
Kim, Dae Joong
Kim, Yong Soo
Kim, Moon Jae
Shin, Sug Kyun
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Wallace Mem Baptist Hosp, Pusan, South Korea
[3] Yeungnam Univ, Taegu, South Korea
[4] Konyang Univ, Taejon, South Korea
[5] Inje Univ, Pusan, South Korea
[6] Kyungpook Natl Univ, Taegu, South Korea
[7] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[8] Catholic Univ, Seoul, South Korea
[9] Inha Univ, Inchon, South Korea
[10] Ilsan Hosp, Natl Hlth Insurance Corp, Seoul, South Korea
关键词
CAPD; glucose degradation products; patient survival; pH neutral; prescribing practices;
D O I
10.1093/ndt/gfl393
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Novel, biocompatible peritoneal dialysis (PD) solutions have become available in recent years. In 2001, low glucose degradation products (GDP), neutral pH solutions became commercially available in Korea. To date, there are no reports regarding the large scale adoption of these solutions in clinical practice and regarding what, if any, impact these solutions have on patient outcomes. Methods. Using a database of almost 4000 patients treated by PD in Korea, we conducted a prospective, longitudinal observational study documenting the patterns of use of one novel low GDP solution (balance (R), Fresenius Medical Care, St Wendel, Germany) in 1909 PD incident patients between 1 January 2002 and midyear 2005. Outcomes including patient and technique survival and peritonitis rates were analysed using univariate and multivariate analysis. Results. Prescription of low GDP solutions reached between 70 and 80% by the year 2003 and persisted at this level. Patients prescribed low GDP PD solution tended to be younger and were more likely to be treated in centres with larger enrolment in the database. Survival of diabetic patients treated with the new PD solution was identical to that of the non-diabetic patients treated with standard PD fluids (PDF) and treatment with low GDP PDF independently reduced the relative risk (RR) of death (RR = 0.613; CI 0.50-0.74; P < 0.00001) in a proportional hazards model which included age, diabetes and centre experience. In a univariate analysis, low GDP PD solution was associated with a longer technique survival (P = 0.049) but this effect was not significant in multivariate analysis. No significant differences in peritonitis-free interval or peritonitis rate could be attributed to the prescribed PDF. Conclusion. Prescription of low GDP, pH-neutral PD solutions has rapidly increased in Korea. This change has resulted in a significant improvement in patient and technique survival without any measurable change in peritonitis incidence or rate. Reasons for the improved patient survival cannot be determined from this analysis and require further study.
引用
收藏
页码:2893 / 2899
页数:7
相关论文
共 20 条
[1]   A new lactate-based, plasticizer-free, neutral peritoneal dialysis fluid provided in a two-compartment system: Effect on peripheral leukocyte function [J].
Alscher, DM ;
Pauli-Magnus, C ;
Kirchgessner, J ;
Kuhlmann, U ;
Mettang, T .
NEPHRON, 2000, 86 (01) :62-69
[2]  
Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158
[3]  
Brown F, 2006, PERITON DIALYSIS INT, V26, P112
[4]   Association between residual renal function inflammation and patient survival in new peritoneal dialysis patients [J].
Chung, SH ;
Heimbürger, O ;
Stenvinkel, P ;
Qureshi, AR ;
Lindholm, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (03) :590-597
[5]   In vitro evidence for immune activating effect of specific AGE structures retained in uremia [J].
Glorieux, G ;
Helling, R ;
Henle, T ;
Brunet, P ;
Deppisch, R ;
Lameire, N ;
Vanholder, R .
KIDNEY INTERNATIONAL, 2004, 66 (05) :1873-1880
[6]  
Haag-Weber M, 2003, J AM SOC NEPHROL, V14, p476A
[7]   Advanced glycation end products in kidney transplant patients: A putative role in the development of chronic renal transplant dysfunction [J].
Hartog, JWL ;
Smit, AJ ;
van Son, WJ ;
Navis, G ;
Gans, ROB ;
Wolffenbuttel, BHR ;
de Jong, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (06) :966-975
[8]   Current status of dialytic therapy in Korea [J].
Kim, SY ;
Jin, DC ;
Bang, BK .
NEPHROLOGY, 2003, 8 :S2-S9
[9]  
Lee HY, 2005, PERITON DIALYSIS INT, V25, P248
[10]   Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane [J].
Mortier, S ;
De Vriese, AS ;
Mcloughlin, RM ;
Topley, N ;
Schaub, TP ;
Passlick-Deetjen, J ;
Lameire, NH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05) :1296-1306